| Risk factors for hospitalization and mortality due to dengue fever in a Mexican population: a retrospective cohort study R Fonseca-Portilla, M Martínez-Gil, D Morgenstern-Kaplan International Journal of Infectious Diseases 110, 332-336, 2021 | 22 | 2021 |
| Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients R Fonseca, M Arribas, JE Wiedmeier-Nutor, YN Kusne, M González Vélez, ... Blood cancer journal 13 (1), 32, 2023 | 13 | 2023 |
| Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma SJ Welsh, BG Barwick, EW Meermeier, DL Riggs, CX Shi, YX Zhu, ... Blood cancer discovery 5 (1), 34-55, 2024 | 10 | 2024 |
| Sudden unexpected infant death: review and analysis of adherence to recommendations E Konstat-Korzenny, A Cohen-Welch, R Fonseca-Portilla, ... Cureus 11 (11), 2019 | 10 | 2019 |
| Targeting TMPRSS2 in SARS-CoV-2 Infection, vol. 95, no. 9, 2020Mayo Clinic Proceedings LB Baughn, N Sharma, E Elhaik, A Sekulic, AH Bryce, R Fonseca Elsevier, 2020 | 6 | 2020 |
| Lessons from the COVID-19 pandemic: knowledge and preventive actions among a mexican population sample E Konstat-Korzenny, D Morgenstern-Kaplan, R Fonseca-Portilla, ... Archivos de Medicina (Col) 21 (1), 247-260, 2021 | 5 | 2021 |
| Conocimiento sobre la diabetes mellitus tipo 2 en estudiantes universitarios: Un estudio transversal y observacional en la Universidad Anáhuac México Campus Norte en la Ciudad … E Konstat-Korzenny, R Fonseca-Portilla, S Majzner-Aronovich, ... Rev. chil. endocrinol. diabetes 11 (4), 156-160, 2018 | 4 | 2018 |
| Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma N Thongon, F Ma, N Baran, P Lockyer, J Liu, C Jackson, A Rose, ... Nature communications 15 (1), 1203, 2024 | 2 | 2024 |
| Beyond the Primary: Unveiling the Prognostic Value of Secondary Cytogenetic Abnormalities in Multiple Myeloma R Fonseca, M Arribas, G Ahmann, JC Castro, EE Wiedmeier-Nutor, ... Blood 142, 2000, 2023 | 1 | 2023 |
| Physicians’ Perspectives on HL7 Information Policy Sensitive Value Set: A Validation Study through Health Concept Categorization M Eluru, DH Mendoza, A Wong, M Jafari, M Todd, P Bayless, D Chern, ... Healthcare 11 (21), 2845, 2023 | 1 | 2023 |
| LP-118, a Novel BCL2 Inhibitor, Shows Potent in Vitro Anti-Myeloma Activity R Fonseca, YX Zhu, PL Bergsagel, M Chesi, A Pandey, K Mangalaparthi, ... Blood 140 (Supplement 1), 7129-7130, 2022 | 1 | 2022 |
| Safety Profiles of Bispecific Antibodies in Non-Hodgkin Lymphoma: A Meta-Analysis of Phase I-III Trials R Fonseca, A Liu, B Langlais, D Almader-Douglas, H Vikram, T Hilal Clinical Lymphoma, Myeloma and Leukemia 24, S220, 2024 | | 2024 |
| ABCL-699 Safety Profiles of Bispecific Antibodies in Non-Hodgkin Lymphoma: A Meta-Analysis of Phase I-III Trials R Fonseca, A Liu, B Langlais, D Almader-Douglas, H Vikram, T Hilal Clinical Lymphoma Myeloma and Leukemia 24, S489, 2024 | | 2024 |
| Prevalence of adverse events following bispecific antibody therapy in non-Hodgkin lymphoma: A meta-analysis. AJ Liu, R Fonseca, B Langlais, D Almader-Douglas, T Hilal Journal of Clinical Oncology 42 (16_suppl), e19008-e19008, 2024 | | 2024 |
| Amyloidosis & Cardiac Transplant: A New Frontier J Farina, M Lyle, E Wiedmeier-Nutor, V Lindpere, M Klanderman, ... The Journal of Heart and Lung Transplantation 43 (4), S233, 2024 | | 2024 |
| Correction: Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients R Fonseca, M Arribas, JE Wiedmeier-Nutor, YN Kusne, MG Vélez, ... Blood cancer journal 13 (1), 2023 | | 2023 |
| P-177 Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma (MM) S Welsh, B Barwick, E Meermeier, D Riggs, CX Shi, M Sharik, M Du, ... Clinical Lymphoma Myeloma and Leukemia 23, S132-S133, 2023 | | 2023 |
| S185: TARGETING DNA2 OVERCOMES METABOLIC REPROGRAMMING IN 1Q21 MULTIPLE MYELOMA N Thongon, MA Feiyang, P Lockyer, N Baran, J Liu, C Class, L Tan, ... HemaSphere 7, e91269c8, 2023 | | 2023 |
| Electrocardiogram As a Marker of Cardiac Response in Light Chain Amyloidosis R Fonseca, Y Kusne, M Arribas, M Klanderman, JE Wiedmeier, E Muchtar, ... Blood 140 (Supplement 1), 12566-12567, 2022 | | 2022 |
| IMiDs Synergize with EP300 Inhibition to Disrupt the Ikzf/MYC/IRF4 Axis in Multiple Myeloma SJ Welsh, BG Barwick, E Meermeier, D Riggs, CX Shi, YX Zhu, ME Sharik, ... Blood 140 (Supplement 1), 12997-12997, 2022 | | 2022 |
